Policy & Regulation
ForDoz Pharma signs manufacturing contract with LipoMedix
22 February 2021 -

United States-based ForDoz Pharma has signed contract with Israel-based LipoMedix.

It was reported on Friday that the contract has been signed for Fordoz to manufacture LipoMedix's lead compound, pegylated liposomal Promitil (PL-MLP) for a Phase two clinical study. The product is designed for selective delivery of the therapeutic agent to cancer-affected tissues and is ideally suited for cancer chemoradiotherapy.

James He, ForDoz founder and CEO, said, 'Our mission is to ultimately aid in the delivery of innovative medicines that will help people live longer and better lives. We are proud to partner with LipoMedix to help them develop and manufacture Promitil here in the United States.'